PHOTOMEDEX RECEIVES TWO NEW PATENTS FOR COPPER PEPTIDE TECHNOLOGY
Montgomeryville, Pa.-based PhotoMedex has announced that it has received two new U.S. patents covering the use of its copper peptide compounds in dermatological skin disorders. The patents - #6,927,205 B2 and #6,927,206 B2 - anticipate the use of a variety of certain active agents, including active drug and active cosmetic substances, with the ProCyte copper peptide technology when treating skin diseases.
These new patents originate from a series of patents previously filed by ProCyte and currently in a review process covering new applications and combinations of the GHK and AHK copper peptides and other metallic peptides.
According to PhotoMedex president and CEO Jeff O'Donnell, "The newly issued patents add to our intellectual property base and provide new avenues to explore individual and/or combination therapies that may accelerate or in other ways improve existing treatments in dermatology that could lead to better patient results."